Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Biotechnology

Healthcare
$43.11 +5.87%

+$4.49 today

Market cap
$6.09B
Beta
1.27
P/E (TTM)
-38.4
EPS (TTM)
-$2.11
52W Low $14.30High $82.48

Volume 2.42M

Average 1.82M

ARWR Cost of Revenue

Direct costs of producing the goods and services sold, such as materials, manufacturing, and service delivery.

Arrowhead Pharmaceuticals, Inc.NASDAQ: ARWR

Cost of Revenue · Q4 FY2026 · quarter ended Sep 2026

Cost of revenue remains negative

Q4 FY2026 cost of revenue was $1.8M, compared with $0 a year earlier. Trailing-twelve-month cost of revenue was $1.8M. Over 3 fiscal years it compounded at -47.6% a year.

Context

  • Cost of revenue amounted to 0.4% of revenue in FY2026, up 0.4 pp from a year earlier.
  • Cost of revenue increased in 2 of the last 3 fiscal years.

What to watch

Whether quarterly cost of revenue holds near $1.8M or moves back toward the trailing-twelve-month quarterly average of $449.75K.

Sources:Income StatementText generated from reported figures; not investment advice.

Latest quarterSep 2026
$1.8M— QoQ
Last fiscal yearSep 2026
$1.8M— YoY
LTMSep 2026
$1.8M— YoY
Cost of Revenue past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year———
3-year CAGR-47.6%——
5-year CAGR——
10-year CAGR——

Cost of Revenue history

USD · from the income statement

Latest · FY2026
1.8M USD
Year-over-year change
—
4-year CAGR
-35.5%

Cost of Revenue vs competitors

How ARWR compares with its peers on the latest reported figures

  • Peers report in different currencies, so cost of revenue is compared through growth and share of revenue rather than absolute size.
  • Cost of revenue amounts to 0.4% of revenue for ARWR, versus a peer median of 9.5%.
ARWR Competitors
Cost of Revenue for ARWR and competitors
Company Period LTM YoY 3-year CAGR% of revenue
ALNYAlnylam Pharmaceuticals, Inc.LTM Jun 2026$974.34M USD+141.9%+58.9%20.3%
IONSIonis Pharmaceuticals, Inc.LTM Sep 2026$17.04M USD+44.2%+4.3%1.8%
WVEWave Life Sciences Ltd.LTM Mar 2026$4.46M USD+106.0%—6.2%
ARCTArcturus Therapeutics Holdings Inc.LTM Mar 2026$4M USD——8.8%
ARWRArrowhead Pharmaceuticals, Inc.LTM Sep 2026$1.8M USD—-47.6%0.4%
PRQRProQR Therapeutics N.V.LTM Mar 2026€1.38M EUR——10.3%
SLNSilence Therapeutics plcLTM Mar 2026$309.37K USD—-73.0%33.6%
Peer median (excluding ARWR) —+106.0%+4.3%9.5%

Competitors are the stored peer set for ARWR. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Income Statement

USD
Metric
FY2022
Sep 2022
FY2023
Sep 2023
FY2024
Sep 2024
FY2025
Sep 2025
FY2026
Sep 2026
Revenue243.23M240.74M3.55M829.45M450.82M
Cost of Revenue10.42M12.49M18.6M01.8M
Gross Profit232.81M228.24M(15.04M)829.45M449.02M
Gross Margin95.7%94.8%-423.7%100.0%99.6%
Research & Development288.5M342.31M489.22M607.16M739.14M
Selling, General & Admin124.43M90.93M96.82M121.92M202.05M
Operating Expenses411.32M433.24M586.04M731.1M1.16B
Depreciation & Amortization10.42M12.49M18.6M23.93M26.62M
EBITDA(162.29M)(175.67M)(561.51M)164.82M(603.59M)
EBITDA Margin-66.7%-73.0%-15812.8%19.9%-133.9%
Operating Income(178.51M)(205M)(601.08M)98.35M(707.17M)
Operating Margin-73.4%-85.2%-16927.1%11.9%-156.9%
Interest Income5.03M15.3M22.72M37.29M57.86M
Interest Expense018.33M32.35M89.36M93.71M
Other Income / Expenses5.8M(1.49M)(11.38M)(46.81M)(16.74M)
Income Before Tax(172.71M)(206.49M)(612.46M)51.53M(723.92M)
Pre-Tax Margin-71.0%-85.8%-17247.5%6.2%-160.6%
Income Tax Expense3.79M2.78M(2.77M)21.42M(6.78M)
Net Income(176.06M)(205.28M)(599.49M)(1.63M)(724.21M)
Net Margin-72.4%-85.3%-16882.4%-0.2%-160.6%
EPS (Basic)(1.67)(1.92)(5.00)(0.01)(5.11)
EPS (Diluted)(1.67)(1.92)(5.00)(0.01)(5.11)
Weighted Avg Shares105.43M106.75M119.78M133.76M141.63M
Weighted Avg Shares (Diluted)105.43M106.75M119.78M133.76M141.63M

Arrowhead Pharmaceuticals, Inc.

NASDAQ:ARWR

Intrinsic Alpha fair value

Locked

Current Price

$43.11

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.